Tedizolid phosphate for injection approved for marketing

Recently, Tedizolid Phosphate for Injection, a drug developed by Qingfeng Pharmaceutical for the treatment of acute bacterial skin and skin soft tissue infections, was officially approved for marketing by the NMPA.

Tedizolid phosphate is a Class IA recommended drug for the treatment of complicated skin and soft tissue infections with suspected or confirmed methicillin-resistant Staphylococcus aureus in the American Society of Surgical Infection's "Guidelines for the Management of Complicated Skin and Soft Tissue Infections" and the World Association of Emergency Surgery/European Society of Surgical Infection's "Consensus on the Management of Skin and Soft Tissue Infections".

Antibiotics are known as one of the greatest inventions of the 20th century. Since the British biologist Sir Fleming discovered penicillin, the first antibiotic in human history, in 1928, it has completely reversed the passive situation of human beings being helpless and waiting to die in the face of bacterial diseases. In recent years, the widespread use of various antibiotics has led to the increasingly serious problem of bacterial resistance, and the emergence of multi-drug resistant bacteria has posed a severe challenge to the public health systems of countries around the world.

Tedizolid phosphate is a second-generation oxazolidinone antibiotic. Compared with the first-generation oxazolidinone antibiotic linezolid, its antibacterial activity is 4 to 16 times higher, and it has fewer adverse reactions in the gastrointestinal tract and thrombocytopenia than linezolid, and the incidence of drug resistance is also lower. In addition, tedizolid phosphate is available in two dosage forms: injection and tablets, which facilitates clinical switching, shortens the patient's hospitalization time, and thus reduces the patient's treatment costs.